| Japanese |
|---|
| Title | 腎癌におけるポジトロン断層法の有用性の検討 (予報) |
|---|
| Subtitle | 研究速報 |
|---|
| Authors | 川村寿一*, 飛田収一**, 吉田修**, 米倉義晴***, 千田道雄***, 山本和高***, 佐治英郎***, 藤田透***, 小西淳二*** |
|---|
| Authors(kana) | |
|---|
| Organization | *三重大学医学部泌尿器科, **京都大学医学部泌尿器科, ***核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 25 |
|---|
| Number | 10 |
|---|
| Page | 1143-1148 |
|---|
| Year/Month | 1988/10 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「I. はじめに」当施設では, ポジトロン断層法(Positron Emission Tomography; PETと略す)を用いて15O標識ガスを用いた脳血流や酸素代謝の測定, 13N-アンモニアおよび2-deoxy-2[18F]fluoro-D-glucose(18F-FDG; FDGと略す)を用いた心筋血流代謝の測定がすでに報告されてきた. また, 肝については, 癌組織と正常組織間でのブドウ糖代謝が異なることに注目して, FDGを用いて陽性腫瘍シンチグラフィの可能性が報告されている. 一方, 腎においてはこのPET応用はまだ未知の分野といわなければならない. 腎癌は各種画像診断法によりその存在診断は容易にされるが, 治療時すでに局所浸潤性が強かったり, 遠隔転移をおこしていることも少なくない. また, 腎癌は各種抗癌剤のききにくいものに属し, 早期診断, 手術的完全摘出が治療成績の向上に必須条件といわなければならない. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Positron emission tomography, Renal cell carcinoma, FDG. |
|---|
| English |
|---|
| Title | Validity of Positron Emission Tomography (PET) Using 2-deoxy-2-[18F]fluoro-D-glucose (FDG) in Patients with Renal Cell Carcinoma (Preliminary Report) |
|---|
| Subtitle | |
|---|
| Authors | Juichi KAWAMURA*, Shuichi HIDA**, Osamu YOSHIDA**, Yoshiharu YONEKURA***, Michio SENDA***, Kazutaka YAMAMOTO***, Hideo SAJI***, Toru FUJITA***, Junji KONISHI*** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Urology, Mie University School of Medicine, **Department of Urology, ***Nuclear Medicine, Faculty of Medicine, Kyoto University |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 25 |
|---|
| Number | 10 |
|---|
| Page | 1143-1148 |
|---|
| Year/Month | 1988/10 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | Positron emission tomography (PET) using 2-deoxy-2[18F]fluoro-D-glucose (FDG) was carried out in 6 patients with renal tumors (5 renal cell carcinomas including one patient in whom the primary renal lesion was nephrectomized and 1 angiomyolipoma) and FDG accumulation was evaluated in the tumor lesion as a "hot spot". In dynamic images after 16 min. FDG accumulated in the tumor portion in 3 out of 4 patients with renal cell carcinoma. However, there was no accumulation in one renal cell carcinoma in which marked necrosis was histologically found. FDG accumulation was not evident in the tumorous lesion of angiomyolipoma. FDG accumulation was also noticed in the metastatic lesion of renal cell carcinoma in the liver or retroperitoneal lymph node. A gradual increase of FDG activity in the lesion of renal cell carcinoma was clearly demonstrated in the time-radioactivity curve, while activities rapidly decreased in renal cortex and pelvis, and liver. In the healthy portion of the kidney, FDG is filtered from the glomerulus and is not reabsorbed from the tubulus and is excreted in the collecting system. On the contrary, FDG, catalyzed by hexokinase, is phospholylated to FDG-6-phosphate which accumulates in the tumor tissue. PET using FDG can provide a new insight for understanding biological activity of renal cell carcinoma from the point of glucose metabolism in tumor tissue. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Positron emission tomography, Renal cell carcinoma, FDG. |
|---|